A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

Recruiting

Phase 1

Phase 2

AZD8421A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

Sponsor:

AstraZeneca

Code:

NCT06188520

Conditions

ER+ HER2- Advanced Breast Cancer

High-grade Serous Ovarian Cancer (HGSOC)

Eligibility Criteria

Sex: Female

Age: 18+

Healthy Volunteers: Not accepted

Interventions

AZD8421

Camizestrant

Ribociclib

Palbociclib

Abemaciclib

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-02. This information was provided to ClinicalTrials.gov by AstraZeneca on 2025-03-26.